FMP
Imago BioSciences, Inc.
IMGO
NASDAQ
Inactive Equity
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
36.01 USD
0 (0%)
About
ceo
Dr. Hugh Young Rienhoff Jr., M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.imagobio.com
exchange
NASDAQ
Description
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
CIK
0001623715
ISIN
US45250K1079
CUSIP
45250K107
Address
329 Oyster Point Boulevard
Phone
415 529 5055
Country
US
Employee
41
IPO Date
Jul 16, 2021
Key Executives
